On March 20, 2019, XVIVO Perfusion AB (publ) announced the notice to attend the Annual General Meeting on Thursday, April 25, 2019. The date entered as record date for participation at the Annual General meeting, April 19, 2019 and the date entered as last application date for participation at the Annual General meeting, Monday, April 22, 2019 where incorrect. Record date has been corrected to Wednesday, April 17, 2019 and the last date for application for participation at the Annual General meeting has been corrected to Tuesday, April 23, 2019.

The notice to attend the Annual General Meeting is otherwise unchanged. The corrected notice is attached as an attachment and is also available on the company's website:

Queries should be addressed to:

Gösta Johannesson, Chairman of the Board, phone +46 8-614 00 20,
Christoffer Rosenblad, CFO, phone +46 735 19 21 59,

The information was submitted for publication on March 25, 2019 at 2:00 p.m.

This is a translation of the summary of the Swedish version of the notice to attend AGM. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website:



Documents & Links